IgG4-Related Disease

IgG4-Related Disease (IgG4-RD) is an immune-mediated fibro-inflammatory condition that can affect virtually any organ in the body, producing tumefactive (mass-forming) swellings, dense scarring, and characteristic tissue changes that were once mistaken for cancer, infection, or entirely separate diseases. Recognized as a unified clinical entity around 2003, IgG4-RD links previously mysterious conditions — autoimmune pancreatitis, Mikulicz disease, Riedel thyroiditis, retroperitoneal fibrosis, and others — under one diagnosis. It responds dramatically to glucocorticoids, which both confirms the diagnosis and rescues organ function, though relapse is common and long-term management is an active area of research.

Table of Contents

  1. Overview
  2. Historical Recognition
  3. Pathophysiology and Immunology
  4. Organ Manifestations
  5. Diagnostic Criteria and Workup
  6. Treatment
  7. Differential Diagnosis
  8. Prognosis and Monitoring
  9. Recent Research and Advances
  10. References
  11. Connections
  12. Featured Videos

Overview

IgG4-Related Disease is a systemic inflammatory condition defined by a triad of histopathological findings: a dense infiltrate of lymphocytes and IgG4-positive plasma cells, storiform (whorled, cartwheel-pattern) fibrosis, and obliterative phlebitis — inflammation that destroys veins from the inside. The resulting lesions are tumefactive, meaning they form firm, tumor-like masses that compress adjacent structures and are frequently misidentified as malignancy on imaging, leading to unnecessary surgery before the diagnosis is recognized.

The disease is systemic: it may strike a single organ or involve several simultaneously or sequentially. The pancreas, salivary and lacrimal glands, bile ducts, orbits, kidneys, aorta, retroperitoneum, lungs, thyroid, and meninges are among the organs most commonly affected. Because each involved organ was historically treated as a separate specialty problem — gastroenterologists managed the pancreas, ophthalmologists the orbit, nephrologists the kidney — the unifying nature of IgG4-RD went unrecognized for decades.

Serum IgG4 is elevated above 135 mg/dL in 60–70% of patients, but this finding is neither sufficient nor required for diagnosis. The gold standard remains tissue biopsy demonstrating the characteristic histology. The ACR/EULAR 2019 classification criteria provide a scoring system integrating histology, immunostaining, radiology, and serology to standardize case identification for research and clinical practice.

Demographics skew toward older men (median age in the 60s–70s), with a notable exception for orbital disease, which affects women more equally. Atopic history — asthma, eczema, food allergy, elevated serum IgE — is present in a substantial minority and may reflect shared immunological predispositions.

Back to Table of Contents

Historical Recognition

The individual conditions that make up IgG4-RD were described over more than a century before their shared identity was understood. Johann von Mikulicz described bilateral painless enlargement of salivary and lacrimal glands in 1892 — now recognized as IgG4-RD of the head and neck. Bernhard Riedel described his eponymous invasive fibrous thyroiditis in 1896. Ormond's disease (retroperitoneal fibrosis) was characterized in 1948. Autoimmune pancreatitis (AIP) was first described in 1961 by Sarles and colleagues, who noted an unusual form of chronic pancreatitis associated with hypergammaglobulinemia and a lack of alcohol history.

The conceptual unification began in 1995 when Yoshida and colleagues proposed the term "autoimmune pancreatitis" for a steroid-responsive inflammatory pancreatic disease distinct from alcoholic or gallstone pancreatitis. The pivotal insight came in 2001, when Hamano and colleagues at Shinshu University, Japan, reported that patients with sclerosing pancreatitis had strikingly elevated serum IgG4 concentrations — a finding published in the New England Journal of Medicine in 2001. This sparked a cascade of re-examination: pathologists and clinicians reviewing archived biopsies of Mikulicz disease, orbital pseudotumor, and retroperitoneal fibrosis found the same IgG4-rich plasma cell infiltrate and storiform fibrosis in all of them.

By 2003, Kamisawa and colleagues proposed that autoimmune pancreatitis and its associated conditions represented a single systemic disease driven by IgG4, coining the term IgG4-related systemic disease. International consensus on nomenclature, histopathological criteria, and management emerged through a series of symposia and working groups in the 2010s, culminating in the 2012 Boston consensus statement on nomenclature and the 2019 ACR/EULAR classification criteria.

The recognition of IgG4-RD is considered one of the most important discoveries in rheumatology and immunology of the early 21st century because it reframed apparently unrelated disorders as one treatable systemic disease, sparing many patients from unnecessary surgery and cancer treatment.

Back to Table of Contents

Pathophysiology and Immunology

The immunopathogenesis of IgG4-RD involves a complex interplay of innate and adaptive immune cells, but the precise initiating trigger remains unknown. Environmental exposures, chronic antigen stimulation, and genetic susceptibility all appear to contribute, but no single driver has been identified. Notably, IgG4 antibodies themselves are likely not the primary pathogenic mediators — the IgG4+ plasma cells are markers of the disease process rather than its cause.

T follicular helper cells and B cells appear to play central roles. Clonally expanded CD4+ cytotoxic T lymphocytes (CTLs) — a population not normally associated with fibroinflammatory disease — have been found in the blood and tissues of IgG4-RD patients. These cells secrete profibrotic cytokines including IL-1β, TGF-β1, and IFN-γ, promoting the storiform fibrosis that is a hallmark of the disease. Macrophages expressing M2 markers (CD163+) are also enriched in lesions and contribute to fibrosis.

Storiform fibrosis — the irregular, whorled pattern of collagen deposition that resembles a storefront mat — results from activated fibroblasts and myofibroblasts responding to TGF-β signaling. This pattern is pathognomonic and distinguishes IgG4-RD from other inflammatory fibroses. Obliterative phlebitis reflects venous endothelial injury and intramural inflammation leading to luminal obliteration; it is best identified in medium-sized veins on elastin or CD34 stains.

The IgG4 subclass itself has unique biochemical properties: it is the smallest IgG subclass, does not fix complement efficiently, and can exchange half-antibody molecules in a process called Fab-arm exchange, producing bispecific antibodies with low inflammatory potential. This explains why extraordinarily high IgG4 levels do not by themselves cause damage — the damage comes from the cellular infiltrate and fibroblast activation, not from antibody-mediated complement killing.

Eosinophilia is mild to moderate in a substantial proportion of patients and correlates with atopic history and elevated serum IgE. Some researchers propose that chronic allergen stimulation may polarize the immune response toward Th2 cytokines (IL-4, IL-5, IL-13), which in turn drive class-switching to IgG4 and IgE. However, a clear atopic trigger has not been established, and many IgG4-RD patients have no atopic history at all.

Back to Table of Contents

Organ Manifestations

IgG4-RD is protean: virtually no organ is immune. The following are the most clinically important sites.

Pancreas (Type 1 Autoimmune Pancreatitis): The most studied manifestation. Type 1 AIP presents with obstructive jaundice, weight loss, new-onset diabetes, and occasionally a pancreatic mass — a picture almost indistinguishable from pancreatic adenocarcinoma. CT shows diffuse or focal pancreatic enlargement with a characteristic capsule-like hypodense halo (the "sausage pancreas" sign). A short biliary stricture with upstream dilation and wall thickening on MRCP is characteristic of IgG4-associated cholangitis (IAC). Dramatic improvement within 2–4 weeks of steroid therapy strongly favors IgG4-RD over cancer.

Salivary and Lacrimal Glands (Mikulicz Disease): Painless bilateral submandibular, parotid, and/or lacrimal gland enlargement. Patients may have dry eyes and dry mouth, closely mimicking primary Sjögren's syndrome. The distinction is important: Mikulicz/IgG4-RD responds well to steroids, while Sjögren's does not. Anti-SSA and anti-SSB antibodies are absent in IgG4-RD; serum IgG4 is elevated; biopsy shows IgG4+ plasma cells without the germinal centers of Sjögren's.

Orbits (IgG4-Associated Orbital Disease): Unilateral or bilateral periorbital swelling, proptosis, diplopia, and eyelid ptosis from infiltration of the orbital fat, lacrimal gland, or extraocular muscles. It was previously called idiopathic orbital inflammatory pseudotumor. Vision loss from optic nerve compression can occur. Contrast-enhanced MRI shows a molding, infiltrative pattern around orbital structures.

Kidneys (IgG4-Related Tubulointerstitial Nephritis): Presents with rising creatinine and CT showing bilateral cortical wedge-shaped or round low-density lesions — a pattern not seen in other renal inflammatory diseases. Membranous nephropathy (immune complex deposition on the glomerular basement membrane causing proteinuria) also occurs. Early treatment prevents permanent renal failure.

Aorta and Retroperitoneum: IgG4-related periaortitis/aortitis presents as thickening of the aortic wall with surrounding soft tissue — a condition associated with inflammatory aortic aneurysm. Retroperitoneal fibrosis (RPF, Ormond's disease) encases the ureters, causing hydronephrosis and renal failure; it also entraps the aorta and inferior vena cava. Up to 30–40% of RPF cases are IgG4-related.

Lungs: Pulmonary nodules, ground-glass opacities, interstitial lung disease, and bronchial wall thickening. Can be misdiagnosed as lung cancer or sarcoidosis.

Thyroid (Riedel Thyroiditis): Rare but severe; invasive fibrosis replaces the thyroid and extends into adjacent neck structures, causing tracheal compression. Unlike Hashimoto's thyroiditis, the process is stone-hard and infiltrates beyond the thyroid capsule.

Pituitary and Meninges: IgG4-related hypophysitis causes pituitary stalk thickening and anterior pituitary failure; IgG4-related pachymeningitis causes diffuse or nodular dural thickening with cranial nerve palsies or intracranial hypertension.

Back to Table of Contents

Diagnostic Criteria and Workup

Diagnosis of IgG4-RD requires careful integration of clinical features, laboratory data, imaging, and histopathology. No single test is diagnostic.

Serum IgG4: The most widely used biomarker, but imperfect. A threshold of >135 mg/dL is elevated; sensitivity is only 60–70% (many biopsy-confirmed cases have normal serum IgG4). Specificity improves at very high levels (>4× the upper limit of normal, i.e., >540 mg/dL), but even marked elevation is not specific — it also occurs in atopic dermatitis, parasitic infection, pemphigus, and some malignancies. Serum IgG4 should never be used alone to diagnose or exclude IgG4-RD.

Biopsy and Histopathology: The cornerstone of diagnosis. Three major histological features are required:

  1. Dense lymphoplasmacytic infiltrate — tissue packed with lymphocytes and plasma cells.
  2. IgG4+ plasma cell count >10 per high-power field (HPF) on immunohistochemistry, with an IgG4+/IgG+ plasma cell ratio >40%.
  3. Storiform fibrosis and/or obliterative phlebitis.
Eosinophilic infiltration supports but is not required. The histological criteria must be interpreted in context — some organs (e.g., liver, meninges) produce fewer IgG4+ cells even in confirmed disease.

Imaging: CT and MRI typically show diffuse or focal organ enlargement with soft tissue masses. FDG-PET/CT is increasingly used to map disease extent and monitor treatment response — active IgG4-RD lesions are hypermetabolic on PET. Characteristic findings include the pancreatic sausage sign, orbital molding, renal cortical wedge defects, and retroperitoneal soft tissue encasing the aorta.

ACR/EULAR 2019 Classification Criteria: Published by Wallace et al. in 2020, these criteria use a step-wise approach: (1) Entry criteria — characteristic clinical or radiologic involvement of a typical IgG4-RD organ; (2) Exclusion criteria — rule out alternative diagnoses (malignancy, infection, vasculitis, sarcoidosis, Castleman disease, etc.); (3) Inclusion criteria — weighted positive points assigned for histology, immunostaining, radiology, and serology. A total score ≥20 classifies the patient as having IgG4-RD with high specificity. These criteria are designed for research classification, but guide clinical practice.

Additional workup includes complete blood count (eosinophilia), comprehensive metabolic panel (renal function, liver enzymes), urinalysis (proteinuria in membranous nephropathy), ANA/anti-dsDNA/anti-SSA/anti-SSB/ANCA (to exclude lupus, Sjögren's, and vasculitis), complement levels, and serum protein electrophoresis.

Back to Table of Contents

Treatment

IgG4-RD is almost uniquely rewarding to treat: first-line glucocorticoids produce dramatic improvement in most patients within days to weeks, a response so characteristic that failure to respond should prompt re-evaluation of the diagnosis.

Glucocorticoids (First Line): Standard induction is prednisone 30–40 mg/day (or 0.6 mg/kg/day) for 2–4 weeks, followed by a gradual taper over 3–6 months, often reaching a low maintenance dose of 5 mg/day for up to 3 years. The 2015 Japanese consensus guidelines recommend continuing low-dose maintenance for up to 3 years to reduce relapse; Western guidelines are less uniform on maintenance duration. Organ swelling resolves, serum IgG4 falls, and constitutional symptoms disappear. Fibrotic lesions improve but may not fully resolve — established storiform fibrosis is less reversible than active inflammation.

Rituximab (Anti-CD20 B-cell Depletion): The most evidence-based option for relapsing or refractory disease. Rituximab 375 mg/m² IV weekly ×4 doses, or 1000 mg ×2 doses 2 weeks apart, reliably induces remission even in patients who have failed glucocorticoids. Mechanistically, B-cell depletion targets the plasmablast precursors that differentiate into IgG4+ plasma cells; serum IgG4 and plasmablast counts fall rapidly after rituximab. Re-treatment on relapse (retreatment cycles) is effective. Randomized trial data (Stone et al., 2017) confirmed superiority over observation for remission induction.

Conventional Immunosuppressants (Maintenance): Azathioprine, mycophenolate mofetil, and methotrexate are used as steroid-sparing maintenance agents, particularly in patients who cannot tolerate prolonged glucocorticoid use or who have relapsed. Evidence is largely observational, and none of these agents has been tested in a randomized controlled trial for IgG4-RD specifically.

Inebilizumab (Anti-CD19): A next-generation B-cell depleting agent that targets CD19, which is expressed on a broader B-cell lineage than CD20, including some plasmablasts and plasma cell precursors that escape rituximab. A phase 3 randomized controlled trial (MITIGATE) demonstrated that inebilizumab significantly reduced the risk of IgG4-RD flares and organ damage compared with placebo in a global multicenter study, with results published in 2023. It represents the first targeted therapy for IgG4-RD approved in a pivotal trial setting.

Surgery may still be required when obstructive complications are advanced (e.g., hydronephrosis requiring ureteral stenting, biliary obstruction requiring endoscopic stenting, or aortic aneurysm repair) — but surgery alone does not treat the underlying disease, and medical management must follow.

Watchful waiting may be appropriate for asymptomatic disease with no threatened organ function, though most experts favor treatment given the risk of progressive fibrosis.

Back to Table of Contents

Differential Diagnosis

Because IgG4-RD mimics malignancy, infection, and other systemic inflammatory diseases, a broad differential must be systematically excluded before committing to the diagnosis. The ACR/EULAR exclusion criteria codify this step.

Malignancy: Pancreatic adenocarcinoma is the most feared diagnostic confusion — both present with a pancreatic mass, jaundice, and weight loss in older patients. Lymphoma can mimic IgG4-RD in any organ. A characteristic CT sausage sign, IgG4 serology, and steroid trial (with repeat imaging) help distinguish; if doubt persists, EUS-guided biopsy or surgical resection may be necessary. Crucially, steroid therapy should not be given empirically without adequate biopsy in situations where cancer cannot be excluded.

Primary Sjögren's Syndrome: Bilateral gland enlargement and sicca symptoms overlap with Mikulicz/IgG4-RD. Anti-SSA and anti-SSB antibodies, lip biopsy showing focal lymphocytic sialadenitis with focus score ≥1, and a different pattern of lymphocytic infiltration on histology distinguish Sjögren's. The two conditions can rarely coexist.

Sarcoidosis: Pulmonary nodules, bilateral hilar lymphadenopathy, and multisystem granulomatous inflammation closely resemble IgG4-RD. Biopsy showing non-caseating granulomas (absent in IgG4-RD) and elevated serum ACE distinguish sarcoidosis.

Granulomatosis with Polyangiitis (GPA, formerly Wegener's): Orbital, sinus, pulmonary, and renal involvement overlaps with IgG4-RD. ANCA (anti-PR3) seropositivity, necrotizing granulomatous inflammation, and glomerulonephritis with crescent formation on biopsy identify GPA.

Multicentric Castleman Disease: Lymph node-predominant hyperplasia with systemic inflammation, elevated IL-6, and immunostaining showing IgG4+ cells (though not meeting IgG4-RD thresholds). POEMS syndrome and HHV-8-associated MCD require specific exclusion.

Primary Sclerosing Cholangitis (PSC): IgG4-associated cholangitis (IAC) can mimic PSC on cholangiogram. IAC responds to steroids; PSC does not. Serum IgG4 >4× normal, proximal biliary stricture, and periductal IgG4+ plasma cell infiltration on biopsy favor IAC.

Malignant lymphoma, inflammatory myofibroblastic tumor, Erdheim-Chester disease, and Rosai-Dorfman disease are additional histological mimics requiring immunohistochemical differentiation.

Back to Table of Contents

Prognosis and Monitoring

The natural history of IgG4-RD ranges from a single self-limited episode in one organ to a relapsing, multi-organ, fibrotic disease that progressively destroys organ architecture. Several factors influence outcome.

Relapse risk: Approximately 30–50% of patients relapse after steroid discontinuation. Relapse is more likely in patients with multiorgan disease, proximal bile duct involvement (IgG4-associated cholangitis), very high serum IgG4 at diagnosis, and failure to achieve normal serum IgG4 during remission. The IgG4-RD Responder Index (IgG4-RD RI) is a validated composite score integrating organ-specific disease activity and damage that enables standardized assessment across visits and clinical trials.

Organ damage: Fibrosis can accumulate even with treatment. Pancreatic exocrine insufficiency (malabsorption, steatorrhea) and endocrine failure (diabetes mellitus) may persist after pancreatic inflammation resolves. Renal impairment can be permanent if tubulointerstitial nephritis is treated late. Retroperitoneal fibrosis may cause irreversible ureteral obstruction. Early recognition and treatment are critical to preventing irreversible fibrosis.

Malignancy risk: Several registry and cohort studies have raised concern that patients with IgG4-RD have an elevated risk of certain malignancies, particularly lymphoma and pancreatic cancer — though it remains unclear whether this is causal (chronic immune stimulation → lymphomagenesis) or due to diagnostic overlap. Ongoing longitudinal registries are addressing this question. Clinicians should maintain cancer surveillance, particularly when disease is resistant to treatment or atypical in presentation.

Monitoring during remission typically includes serial serum IgG4 levels, organ-specific biomarkers (creatinine, liver enzymes, amylase/lipase), and interval imaging of previously affected organs. Plasmablast counts (CD19+CD38+CD27+IgD− cells by flow cytometry) are an emerging biomarker that tracks disease activity more precisely than serum IgG4 and may predict relapse before clinical symptoms recur.

Glucocorticoid toxicity is a major morbidity in older patients who require prolonged treatment: osteoporosis, hyperglycemia, cataracts, infection risk, and adrenal insufficiency are common. Steroid-sparing strategies and early transition to rituximab-based maintenance are increasingly favored to limit cumulative steroid exposure.

Back to Table of Contents

Recent Research and Advances

IgG4-RD research has accelerated dramatically since 2010, with discoveries reshaping understanding of both the disease and broader immune-mediated fibrosis.

CD4+ Cytotoxic T Lymphocytes (CTLs): Work from Mattoo et al. (2016) identified clonally expanded CD4+SLAMF7+ cytotoxic T cells as central orchestrators of IgG4-RD. These cells, not IgG4 antibodies, produce the fibrogenic cytokines TGF-β1 and IL-1β that activate fibroblasts. This discovery pointed to CD4+ CTLs as potential therapeutic targets beyond B-cell depletion.

MITIGATE Trial (Inebilizumab): The first phase 3 randomized controlled trial for IgG4-RD, published by Stone et al. in the New England Journal of Medicine in 2023, showed that inebilizumab (anti-CD19 monoclonal antibody) reduced IgG4-RD flares by approximately 87% compared with placebo over 52 weeks. This trial established the first FDA-approved-pathway treatment for IgG4-RD and validated B-cell lineage targeting as a disease-modifying strategy.

Multi-organ phenotyping: Large international registries (North American IgG4-RD Registry, European Reference Network) have clarified that patients cluster into distinct phenotypes: a predominantly pancreato-biliary group, a head and neck dominant group, a retroperitoneal/aortic group, and a diffuse multiorgan group — each with different demographics, serology, and treatment response. This phenotyping is informing precision medicine approaches.

Biomarkers: Serum plasmablast counts (CD19+CD38+CD27+IgD−) are more sensitive and specific than serum IgG4 for tracking active disease and predicting flare. Elevated periostin, a matrix protein secreted by fibroblasts, correlates with fibrotic burden. MicroRNA panels and proteomics studies are identifying additional candidate biomarkers for early detection and treatment monitoring.

Genetic associations: HLA-DRB1*04:05 is associated with type 1 AIP in Japanese populations; other HLA alleles have been implicated in European cohorts. Non-HLA susceptibility loci are being identified through genome-wide association studies (GWAS).

Gut microbiome: Preliminary studies suggest dysbiosis in IgG4-RD patients, with alterations in microbiome composition correlating with disease activity and serum IgG4 levels — raising questions about whether gut antigens drive the systemic IgG4 response in susceptible individuals.

Back to Table of Contents

References

  1. Hamano H, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344(10):732–738. PMID 11236777
  2. Kamisawa T, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol. 2003;38(10):982–984. PMID 14614606
  3. Stone JH, et al. IgG4-related disease. N Engl J Med. 2012;366(6):539–551. PMID 22316447
  4. Deshpande V, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181–1192. PMID 22596100
  5. Wallace ZS, et al. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. Arthritis Rheumatol. 2020;72(1):7–19. PMID 31793250
  6. Mattoo H, et al. Clonal expansion of CD4+ cytotoxic T lymphocytes in patients with IgG4-related disease. J Allergy Clin Immunol. 2016;138(3):825–838. PMID 27130856
  7. Carruthers MN, et al. The diagnostic utility of serum IgG4 concentrations in patients with clinically suspected IgG4-related disease. Ann Rheum Dis. 2012;71(8):1330–1334. PMID 22387729
  8. Khosroshahi A, et al. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore). 2012;91(1):57–66. PMID 22198491
  9. Della-Torre E, et al. B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease. Ann Rheum Dis. 2015;74(12):2236–2243. PMID 25467294
  10. Umehara H, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22(1):21–30. PMID 21979375
  11. Stone JH, et al. Inebilizumab for IgG4-Related Disease (MITIGATE). N Engl J Med. 2023;389(22):2024–2037. PMID 38055253
  12. Perugino CA, Stone JH. IgG4-related disease: an update on pathophysiology and implications for clinical care. Nat Rev Rheumatol. 2020;16(12):702–714. PMID 33033404

Back to Table of Contents

Connections

Back to Table of Contents